Account

Home
BMC Cancer
Article
Peer review reports

Peer review reports

From: Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial

Original Submission
21 Mar 2019	Submitted	Original manuscript
3 Oct 2018	Reviewed	Reviewer Report - Reviewer 2
Resubmission - Version 2
	Submitted	Manuscript version 2
Publishing
28 Mar 2019	Editorially accepted
14 Jun 2019	Article published	10.1186/s12885-019-5541-4

Learn about peer review

Back to article page